Soliris vs Ultomiris
Side-by-side cost comparison based on Medicare Part D data
Soliris
Eculizumab
Manufactured by Alexion
Ultomiris
Ravulizumab
Manufactured by Alexion
Ultomiris costs 5% less per claim than Soliris ($65,292.00 vs $68,556.00). A generic version of Ultomiris is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Soliris | Ultomiris |
|---|---|---|
| Avg Cost Per Claim | $68,556.00 | $65,292.00 |
| Total Medicare Spending | $1.2B | $1.6B |
| Total Beneficiaries | 3,600 | 4,800 |
| Total Claims | 18,000 | 24,000 |
| Annual Cost/Patient | $342,778.00 | $326,458.00 |
| Year-over-Year Change | -8.4% | +32.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Alexion | Alexion |
| Condition | Blood Disorders | Blood Disorders |
| Generic Name | Eculizumab | Ravulizumab |
Soliris vs Ultomiris: What the Data Shows
Soliris (Eculizumab) and Ultomiris (Ravulizumab) are both used to treat blood disorders. Based on Medicare Part D data, Ultomiris costs $65,292.00 per claim, which is 5% less than Soliris at $68,556.00 per claim.
Medicare spent $1.2B on Soliris and $1.6B on Ultomiris. In terms of patient reach, Ultomiris serves more beneficiaries (4,800 vs 3,600).
Year-over-year spending changed -8.4% for Soliris and +32.4% for Ultomiris. Ultomiris saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Ultomiris is cheaper at $65,292.00 per claim, compared to $68,556.00 for Soliris. That makes Ultomiris about 5% less expensive per claim based on Medicare Part D data.
Yes, both Soliris and Ultomiris are used to treat blood disorders. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Eculizumab and generic Ravulizumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.2B on Soliris covering 3,600 beneficiaries, and $1.6B on Ultomiris covering 4,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.